HAEMONETICS CORP — Director's Dealing 2010

Aug 2, 2010

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: HAEMONETICS CORP (HAE)
CIK: 0000313143
Period of Report: 2010-07-29

Reporting Person: BEST LAWRENCE C (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2010-07-29	Common Stock	A	1193	$0.01	Acquired	2201	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2010-07-29	Non-Qualified Stock Option (right to buy)	$54.48	A	4290	Acquired	2017-07-29	Common Stock (4290)	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Non-Qualified Stock Option (right to buy)	$20.465	2013-08-22	Common Stock (20000)	20000	Direct
Non-Qualified Stock Option (right to buy)	$26.105	2014-05-05	Common Stock (6000)	6000	Direct
Non-Qualified Stock Option (right to buy)	$44.74	2015-09-02	Common Stock (6000)	6000	Direct
Non-Qualified Stock Option (right to buy)	$49.92	2014-08-01	Common Stock (4592)	4592	Direct
Non-Qualified Stock Option (right to buy)	$52.76	2013-05-05	Common Stock (6000)	6000	Direct
Non-Qualified Stock Option (right to buy)	$58.46	2018-07-31	Common Stock (5664)	5664	Direct
Non-Qualified Stock Option (right to buy)	$59.44	2016-07-30	Common Stock (5879)	5879	Direct

Footnotes

F1: Restricted Stock Unit Grant which vest 100% on the first anniversary of the grant date. Grant was made under 2005 Long Term Incentive Compensation Plan.

F2: Total includes Restricted Stock Awards and/or Restricted Stock Units that are subject to restrictions until vesting requirements are met. Grant was made under 2005 Long Term Incentive Compensation Plan.

F3: Grant to reporting person of right to buy shares of common stock exercisable 100 percent on the first anniversary of the date of grant.

F4: Grant to reporting person of right to buy shares of common stock exercisable immediately.